All In Biotech

Drug Trial Radar · NCT04656418

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Jan 27, 2021

Primary completion

Jun 7, 2022

Study completion Jun 7, 2022

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.

Conditions

  • Hereditary Angioedema

Interventions

  • CSL312Biological

    Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody

  • PlaceboDrug

    Buffer without active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment PeriodTime frame: First injection up to 6 months

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama

    Birmingham, Alabama

  • Medical Research of Arizona

    Scottsdale, Arizona

  • Raffi Tachdjian MD, Inc.

    Santa Monica, California

  • Allergy and Asthma Clinical Research

    Walnut Creek, California

  • Institute of Asthma and Allergy

    Chevy Chase, Maryland

  • Bernstein Clinical Research Center LLC

    Cincinnati, Ohio

  • Pennsylvania State University

    Hershey, Pennsylvania

  • AARA Research Center

    Dallas, Texas

  • Clinique specialisee en allergie de la Capitale

    Québec, Canada

  • University of Alberta - Research Transition Facility

    Edmonton, Alberta, Canada

  • Ottawa Allergy Research Corp

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research Inc.

    Toronto, Ontario, Canada

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • CRC Clinical Research / Hautklinik und Poliklinik der Universitätsklinik Mainz

    Mainz, Germany

  • HZRM Hämophilie Zentrum Rhein Main GmbH

    Mörfelden-Walldorf, Germany

  • Universitätsklinikum Frankfurt Goethe-Universität

    Frankfurt am Main, Hesse, Germany

  • Semmelweis University

    Budapest, Hungary

  • Barzilai University Medical Center

    Ashkelon, Israel

  • Saiyu Soka Hospital

    Saitama, Japan

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • St.Marianna University School of Medicine Hospital

    Kawasaki-shi, Kanagawa, Japan

  • Saitama Medical Center

    Saitama, Kawagoe-shi, Japan

  • Saga University Hospital

    Saga, Saga-shi, Japan

  • Koga Community Hospital

    Yaizu-shi, Shizuoka, Japan

  • Juntendo University Hospital

    Bunkyo, Tokyo, Japan

  • Amsterdam UMC, Location AMC

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.